Background There is considerable uncertainty regarding the optimal haemoglobin threshold
for the use of red blood cell (RBC) transfusions in anaemic patients. Blood is a scarce …

The COVID-19 pandemic has major implications for blood transfusion. There are uncertain
patterns of demand, and transfusion institutions need to plan for reductions in donations and …

Background Recombinant factor VIIa (rFVIIa) is licensed for use in patients with haemophilia
and inhibitory allo‐antibodies. It is also increasingly being used for off‐license indications to …

BACKGROUND: The clinical use of frozen plasma (FP) continues to increase, both in
prophylactic and in therapeutic settings. In 2004, a systematic review of all published randomized …

Background Stem cell therapy offers a promising approach to the regeneration of damaged
vascular and cardiac tissue after acute myocardial infarction (AMI). This has resulted in …

Background A promising approach to the treatment of chronic ischaemic heart disease and
congestive heart failure is the use of stem cells. The last decade has seen a plethora of …

Background This is an update of a Cochrane review first published in The Cochrane Library
in Issue 4, 2006 and previously updated in 2009.

Objective To compare patient outcomes of restrictive versus liberal blood transfusion
strategies in patients with cardiovascular disease not undergoing cardiac surgery. Design …

Rationale: Cell-based therapies are a promising intervention for the treatment of heart
failure (HF) secondary to ischemic and nonischemic cardiomyopathy. However, the clinical …

Introduction Worldwide, trauma is a leading cause of death and disability. Haemorrhage is
responsible for up to 40% of trauma deaths. Recent strategies to improve mortality rates have …